148 related articles for article (PubMed ID: 34938651)
1. Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
Zhang JQ; Zhao BB; Wang MM; Li L
Front Oncol; 2021; 11():603591. PubMed ID: 34938651
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcoma of the ovary: a review of the literature.
del Carmen MG; Birrer M; Schorge JO
Gynecol Oncol; 2012 Apr; 125(1):271-7. PubMed ID: 22155675
[TBL] [Abstract][Full Text] [Related]
3. "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Rauh-Hain JA; Birrer M; Del Carmen MG
Gynecol Oncol; 2016 Aug; 142(2):248-54. PubMed ID: 27321238
[TBL] [Abstract][Full Text] [Related]
4. Management of a rare ovarian carcinosarcoma: A case report and literature review.
Fu J
Exp Ther Med; 2022 Sep; 24(3):583. PubMed ID: 35949347
[TBL] [Abstract][Full Text] [Related]
5. Metastatic ovarian carcinosarcoma in a patient undergoing in-vitro fertilization: A case report.
Flint M; Velasquez J; Carr C; Kolev V; Zakashansky K
Int J Surg Case Rep; 2023 Mar; 104():107937. PubMed ID: 36801768
[TBL] [Abstract][Full Text] [Related]
6. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
7. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
9. Current management of ovarian carcinosarcoma.
Mano MS; Rosa DD; Azambuja E; Ismael G; Braga S; D'Hondt V; Piccart M; Awada A
Int J Gynecol Cancer; 2007; 17(2):316-24. PubMed ID: 17362309
[TBL] [Abstract][Full Text] [Related]
10. Frontiers of Ovarian Carcinosarcoma.
Ismail A; Choi S; Boussios S
Curr Treat Options Oncol; 2023 Dec; 24(12):1667-1682. PubMed ID: 37938504
[TBL] [Abstract][Full Text] [Related]
11. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
[TBL] [Abstract][Full Text] [Related]
12. Ovarian Carcinosarcoma and Response to Immunotherapy.
Daniyal M; Polani AS; Canary M
Cureus; 2023 Apr; 15(4):e37149. PubMed ID: 37153309
[TBL] [Abstract][Full Text] [Related]
13. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
14. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
15. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
16. Niraparib - A promising drug with hematological toxicity.
Patibandla NS; Monga DK
J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Wang Q; Zhang F; Gao H; Xu Y
Ann Palliat Med; 2021 Jan; 10(1):818-827. PubMed ID: 33545804
[TBL] [Abstract][Full Text] [Related]
19. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
[TBL] [Abstract][Full Text] [Related]
20. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
